LIGAND PHARMACEUTICALS INC
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
LGND$314.16+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except par value)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $139,376 | $72,307 |
| Short-term investments | 525,146 | 183,858 |
| Accounts receivable, net | 57,560 | 38,376 |
| Inventory | 11,900 | 14,114 |
| Short-term portion of financial royalty assets, net | 12,416 | 10,025 |
| Income taxes receivable | 536 | 4,073 |
| Other current assets | 6,986 | 8,806 |
| Total current assets | 753,920 | 331,559 |
| Intangible assets, net | 233,535 | 266,648 |
| Goodwill | 101,541 | 105,250 |
| Long-term portion of financial royalty assets, net | 206,332 | 185,024 |
| Noncurrent derivative assets | 9,351 | 10,583 |
| Property and equipment, net | 3,466 | 15,133 |
| Lease right-of-use assets | 7,609 | 9,673 |
| Equity method investments | 42,000 | — |
| Other investments | 106,721 | 10,908 |
| Deferred income taxes, net | 9,526 | 72 |
| Other assets | 2,771 | 6,924 |
| Total assets | $1,476,772 | $941,774 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $3,679 | $5,233 |
| Accrued liabilities | 24,084 | 27,906 |
| Income taxes payable | 1,284 | 1,199 |
| Current contingent liabilities | 268 | 206 |
| Current operating lease liabilities | 1,089 | 1,266 |
| Other current liabilities | 135 | 1,302 |
| Total current liabilities | 30,539 | 37,112 |
| Long-term deferred revenue | — | 2,246 |
| Long-term contingent liabilities | 3,569 | 3,475 |
| Long-term operating lease liabilities | 4,415 | 5,815 |
| Long-term portion of 2030 convertible senior notes, net | 445,493 | — |
| Deferred income taxes, net | 22,673 | 32,524 |
| Other long-term liabilities | 19,912 | 30,163 |
| Total liabilities | 526,601 | 111,335 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 60,000 shares authorized; 19,656 and 19,106 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 20 | 20 |
| Additional paid-in capital | 362,614 | 337,377 |
| Accumulated other comprehensive income (loss) | 9,322 | (5,942) |
| Retained earnings | 578,215 | 498,984 |
| Total stockholders’ equity | 950,171 | 830,439 |
| Total liabilities and stockholders’ equity | $1,476,772 | $941,774 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.